NautaDutilh assisted ATAI Life Sciences N.V. (NASDAQ: ATAI) (“atai”) with its registered underwritten offering of approximately 26 million common shares for net proceeds that are expected to be up to USD 59.1 million.
About atai
atai is a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders, with a bold and ambitious vision: to heal mental health disorders so that everyone, everywhere can live a more fulfilled life.
“It has been an absolute pleasure working alongside Latham & Watkins LLP in this transaction, together assisting atai with this offering. We are honored to support atai in their mission to transform mental health care through innovation and scientific advancement. This milestone reflects the growing recognition of their vision, and we look forward to seeing their continued impact on patients”
Next to Paul and Nina Kielman (lead tax partner) the team consisted of Joppe Schoute, Eline van Marle , and Leanne Meurs.